• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Q32 Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/5/26 7:04:51 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QTTB alert in real time by email
    8-K
    0001661998false00016619982026-05-052026-05-05

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 05, 2026

     

     

    Q32 Bio Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-38433

    47-3468154

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    830 Winter Street

     

    Waltham, Massachusetts

     

    02451

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 781 999-0232

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common stock, par value $0.0001 per share

     

    QTTB

     

    The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 5, 2026, Q32 Bio Inc. announced its financial results for the quarter ended March 31, 2026 and provided a corporate update. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    99.1

    Press Release issued by Q32 Bio Inc. on May 5, 2026

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     



    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Q32 BIO INC.

     

     

     

     

    Date:

    May 5, 2026

    By:

    /s/ Jodie Morrison

     

     

    Name:

    Title:

    Jodie Morrison
    Chief Executive Officer

     


    Get the next $QTTB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QTTB

    DatePrice TargetRatingAnalyst
    5/18/2026Overweight
    Cantor Fitzgerald
    2/25/2026$13.00Buy
    H.C. Wainwright
    2/11/2025$22.00 → $3.00Outperform → Market Perform
    BMO Capital Markets
    2/11/2025$20.00 → $4.00Overweight → Neutral
    Piper Sandler
    12/11/2024Buy → Neutral
    Guggenheim
    12/11/2024$95.00 → $16.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$90.00 → $22.00Strong Buy → Outperform
    Raymond James
    12/11/2024$68.00 → $9.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $QTTB
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Q32 Bio Inc.

    SCHEDULE 13G - Q32 Bio Inc. (0001661998) (Subject)

    6/4/26 5:06:20 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Q32 Bio Inc.

    SCHEDULE 13G - Q32 Bio Inc. (0001661998) (Subject)

    6/4/26 5:01:23 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Q32 Bio Inc.

    SCHEDULE 13D/A - Q32 Bio Inc. (0001661998) (Subject)

    6/1/26 9:10:34 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Xu Diyong bought $15,000,000 worth of shares (1,875,000 units at $8.00) (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    6/1/26 9:15:32 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $15,000,000 worth of shares (1,875,000 units at $8.00) (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    6/1/26 9:13:02 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $QTTB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $QTTB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Q32 Bio Announces $55 Million Private Placement Financing

    WALTHAM, Mass., May 27, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio" or "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors for the private placement of common stock and pre-funded warrants for an aggregate of approximately $55 million.In this private placement, the Company has agreed to issue and sell to such institutional and accredited investors (i) 6,725,000 shares (the "Shares") of the Company's common stock, $0.0001 par

    5/27/26 8:00:00 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

    -- Bempikibart 36-week topline data readout from Part B of SIGNAL-AA Phase 2a clinical trial on-track for mid-2026 ---- First patient dosed in SIGNAL-AA Part B open-label extension (OLE) ---- Completed $10.5 million registered direct offering (RDO) ---- Cash and cash equivalents of $50.8 million as of March 31, 2026, combined with guaranteed near-term milestone payments from ADX-097 asset sale and proceeds from sales under at-the-market (ATM) program received after the end of the quarter, are expected to provide financial runway into 1H'2028 --WALTHAM, Mass., May 5, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innov

    5/5/26 6:59:00 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

    WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 12:45 p.m. E.T. on Wednesday, April 15, 2026 at the 25th Annual Needham Virtual Healthcare Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. An archived replay will be available for 90 days following the event.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targets potent

    4/8/26 6:59:00 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Q32 Bio

    Cantor Fitzgerald initiated coverage of Q32 Bio with a rating of Overweight

    5/18/26 8:36:12 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Q32 Bio with a new price target

    H.C. Wainwright initiated coverage of Q32 Bio with a rating of Buy and set a new price target of $13.00

    2/25/26 7:53:48 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio downgraded by BMO Capital Markets with a new price target

    BMO Capital Markets downgraded Q32 Bio from Outperform to Market Perform and set a new price target of $3.00 from $22.00 previously

    2/11/25 7:55:03 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Xu Diyong bought $15,000,000 worth of shares (1,875,000 units at $8.00) (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    6/1/26 9:15:32 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $15,000,000 worth of shares (1,875,000 units at $8.00) (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    6/1/26 9:13:02 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Violette Shelia M.

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    3/20/26 7:00:05 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Financials

    Live finance-specific insights

    View All

    Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

    WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 12:45 p.m. E.T. on Wednesday, April 15, 2026 at the 25th Annual Needham Virtual Healthcare Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. An archived replay will be available for 90 days following the event.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targets potent

    4/8/26 6:59:00 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

    WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 2:00 p.m. E.T. on Wednesday, February 25, 2026 at the Oppenheimer 36th Annual Healthcare Life Sciences Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following the event.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targe

    2/18/26 6:59:00 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio Sells Complement Inhibitor ADX-097

    -- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the $12 million in upfront and near-term payments upon achievement of certain development, regulatory and commercial milestones and eligible for tiered royalties up to a mid-teen percent of annual net sales --  -- Q32 Bio retains wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other remaining early-stage assets; continuing to evaluate strategic options for these

    12/1/25 7:00:00 AM ET
    $AKBA
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Q32 Bio Inc.

    SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)

    11/14/24 5:46:10 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Q32 Bio Inc.

    SC 13G - Q32 Bio Inc. (0001661998) (Subject)

    11/13/24 4:05:13 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Q32 Bio Inc.

    SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)

    10/25/24 6:06:25 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care